Compare MMA & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MMA | PPCB |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Australia | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 20.4M |
| IPO Year | 2024 | N/A |
| Metric | MMA | PPCB |
|---|---|---|
| Price | $1.12 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 282.7K | 64.7K |
| Earning Date | 01-01-0001 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $739,641.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 191.30 | N/A |
| 52 Week Low | $0.60 | $0.50 |
| 52 Week High | $3.07 | $145.46 |
| Indicator | MMA | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | N/A |
| Support Level | $1.08 | N/A |
| Resistance Level | $1.25 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 23.03 | 0.00 |
Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.